62 related articles for article (PubMed ID: 34112210)
21. How we treat chronic active Epstein-Barr virus infection.
Sawada A; Inoue M; Kawa K
Int J Hematol; 2017 Apr; 105(4):406-418. PubMed ID: 28210942
[TBL] [Abstract][Full Text] [Related]
22. Outcome of L-DEP regimen for treatment of pediatric chronic active Epstein-Barr virus infection.
Ma H; Zhang L; Wei A; Yang J; Wang D; Zhang Q; Zhao Y; Chen S; Lian H; Zhang L; Zhou C; Qin M; Li Z; Wang T; Zhang R
Orphanet J Rare Dis; 2021 Jun; 16(1):269. PubMed ID: 34112210
[TBL] [Abstract][Full Text] [Related]
23. PEG-aspargase and DEP regimen combination therapy for refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
Wang J; Wang Y; Wu L; Zhang J; Lai W; Wang Z
J Hematol Oncol; 2016 Sep; 9(1):84. PubMed ID: 27613189
[TBL] [Abstract][Full Text] [Related]
24. Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents-a life-threatening disease: analysis of 133 cases from a single center.
Lai W; Wang Y; Wang J; Wu L; Jin Z; Wang Z
Hematology; 2018 Dec; 23(10):810-816. PubMed ID: 29957156
[TBL] [Abstract][Full Text] [Related]
25. Clinical analysis of chronic active EBV infection with coronary artery dilatation and a matched case-control study.
Wei A; Ma H; Zhang L; Li Z; Guan Y; Zhang Q; Wang D; Lian H; Zhang R; Wang T
Orphanet J Rare Dis; 2021 Jan; 16(1):50. PubMed ID: 33509232
[TBL] [Abstract][Full Text] [Related]
26. [L-DEP regimen salvage therapy for refractory primary hemophagocytic lymphohistiocytosis triggered by Epstein-Barr virus infection in 4 children].
Zhao YZ; Ma HH; Lian HY; Wang D; Wang TY; Zhang R
Zhonghua Er Ke Za Zhi; 2024 May; 62(5):467-472. PubMed ID: 38623016
[No Abstract] [Full Text] [Related]
27. Characterizing EBV-associated lymphoproliferative diseases and the role of myeloid-derived suppressor cells.
Collins PJ; Fox CP; George L; Pearce H; Ryan G; De Santo C; Mussai F; Lewis D; Long H; Shannon-Lowe C
Blood; 2021 Jan; 137(2):203-215. PubMed ID: 33443553
[TBL] [Abstract][Full Text] [Related]
28. Nationwide survey of systemic chronic active EBV infection in Japan in accordance with the new WHO classification.
Yonese I; Sakashita C; Imadome KI; Kobayashi T; Yamamoto M; Sawada A; Ito Y; Fukuhara N; Hirose A; Takeda Y; Makita M; Endo T; Kimura SI; Ishimura M; Miura O; Ohga S; Kimura H; Fujiwara S; Arai A
Blood Adv; 2020 Jul; 4(13):2918-2926. PubMed ID: 32598475
[TBL] [Abstract][Full Text] [Related]
29. L-DEP regimen salvage therapy for paediatric patients with refractory Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis.
Zhao Y; Li Z; Zhang L; Lian H; Ma H; Wang D; Zhao X; Zhang Q; Wang T; Zhang R
Br J Haematol; 2020 Nov; 191(3):453-459. PubMed ID: 32525580
[TBL] [Abstract][Full Text] [Related]
30. Inherited human IFN-γ deficiency underlies mycobacterial disease.
Kerner G; Rosain J; Guérin A; Al-Khabaz A; Oleaga-Quintas C; Rapaport F; Massaad MJ; Ding JY; Khan T; Ali FA; Rahman M; Deswarte C; Martinez-Barricarte R; Geha RS; Jeanne-Julien V; Garcia D; Chi CY; Yang R; Roynard M; Fleckenstein B; Rozenberg F; Boisson-Dupuis S; Ku CL; Seeleuthner Y; Béziat V; Marr N; Abel L; Al-Herz W; Casanova JL; Bustamante J
J Clin Invest; 2020 Jun; 130(6):3158-3171. PubMed ID: 32163377
[TBL] [Abstract][Full Text] [Related]
31. Oncogenesis of CAEBV revealed: Intragenic deletions in the viral genome and leaky expression of lytic genes.
Murata T; Okuno Y; Sato Y; Watanabe T; Kimura H
Rev Med Virol; 2020 Mar; 30(2):e2095. PubMed ID: 31845495
[TBL] [Abstract][Full Text] [Related]
32. Concomitant
Rodriguez R; Fournier B; Cordeiro DJ; Winter S; Izawa K; Martin E; Boutboul D; Lenoir C; Fraitag S; Kracker S; Watts TH; Picard C; Bruneau J; Callebaut I; Fischer A; Neven B; Latour S
J Exp Med; 2019 Dec; 216(12):2800-2818. PubMed ID: 31537641
[TBL] [Abstract][Full Text] [Related]
33. Advances in the Study of Chronic Active Epstein-Barr Virus Infection: Clinical Features Under the 2016 WHO Classification and Mechanisms of Development.
Arai A
Front Pediatr; 2019; 7():14. PubMed ID: 30805320
[TBL] [Abstract][Full Text] [Related]
34. Activating PIK3CD mutations impair human cytotoxic lymphocyte differentiation and function and EBV immunity.
Edwards ESJ; Bier J; Cole TS; Wong M; Hsu P; Berglund LJ; Boztug K; Lau A; Gostick E; Price DA; O'Sullivan M; Meyts I; Choo S; Gray P; Holland SM; Deenick EK; Uzel G; Tangye SG
J Allergy Clin Immunol; 2019 Jan; 143(1):276-291.e6. PubMed ID: 29800648
[TBL] [Abstract][Full Text] [Related]
35. Activated PI3 Kinase Delta Syndrome: From Genetics to Therapy.
Michalovich D; Nejentsev S
Front Immunol; 2018; 9():369. PubMed ID: 29535736
[TBL] [Abstract][Full Text] [Related]
36. Chronic Active Epstein-Barr Virus Disease.
Kimura H; Cohen JI
Front Immunol; 2017; 8():1867. PubMed ID: 29375552
[TBL] [Abstract][Full Text] [Related]
37.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
38.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
39.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
